Your new post is loading...
French biotech Valneva has revealed additional phase I results concerning its experimental chikungunya vaccine; all 68 patients that were given a single injection of the vaccine showed sustained protection after 12 months. The company is currently running a phase II study and plans to launch a pivotal phase III trial next year.
Valneva's vaccine for the chikungunya virus has proved effective and safe for up to six months after injection in an ongoing phase I trial. By six months after injection, the trial's 120 enrolled volunteers showed no adverse events related to the vaccine, and continued to have antibodies against the virus in their blood. A group of the volunteers was injected with the vaccine for a second time, and showed robust immune protection. The trial will continue to follow the volunteers for up to 13 months after the initial injection. The company expects to announce a plan later this year for how it will work with the FDA to get market approval for the vaccine, which has an FDA Fast Track designation.
